PD-L1 expression in squamous-cell carcinoma and adenocarcinoma of the lung

Radiology and Oncology

Luka Cavka¹  Urska Janzic²  Tanja Cufer³  Izidor Kern⁴  Andrej Janzic⁵ 

[1] Department of Medical Oncology, Institute of Oncology, Ljubljana, SloveniaOther articles by this author:;Department of Medical Oncology, University Clinic Golnik, Golnik, Slovenia;Department of Medical Oncology, University Clinic Golnik, Golnik, SloveniaOther articles by this author:;Department of Pathology, University Clinic Golnik, Golnik, SloveniaOther articles by this author:;University of Ljubljana, Faculty of Pharmacy, Ljubljana, SloveniaOther articles by this author:

关键词: lung cancer;    squamous-cell lung cancer;    adenocarcinoma;    tumor cells;    immune cells;    PD-L1 expression;   

DOI  :  10.1515/raon-2017-0037

学科分类：肿瘤学

来源: Onkoloski Institut Ljubljana / Institute of Oncology Ljubljana

【 摘 要 】

BackgroundWith introduction of immunotherapy (IT) into the treatment of advanced non-small-cell lung cancer (NSCLC), a need for predictive biomarker became apparent. Programmed death ligand 1 (PD-L1) protein expression is most widely explored predictive marker for response to IT. We assessed PD-L1 expression in tumor cells (TC) and immune cells (IC) of squamous-cell carcinoma (SCC) and adenocarcinoma (AC) patients.

【 授权许可】

Unknown